1. Esthesioneuroblastoma: irradiation alone and surgery alone are not enough
- Author
-
Marco Caversaccio, Brigitta G. Baumert, Günther Gruber, Joram Raveh, Richard H. Greiner, and Kurt Laedrach
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Palliative treatment ,medicine.medical_treatment ,Nose Neoplasms ,Esthesioneuroblastoma, Olfactory ,Esthesioneuroblastoma ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Survival rate ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Chemotherapy ,Radiation ,business.industry ,Radiotherapy Dosage ,Middle Aged ,medicine.disease ,Surgery ,Survival Rate ,Oncology ,Tumor progression ,Total dose ,Disease Progression ,Female ,Radiotherapy, Adjuvant ,Nasal Cavity ,business ,Radical resection ,Progressive disease ,Follow-Up Studies - Abstract
To evaluate the long-term outcome of patients with esthesioneuroblastoma treated with neoadjuvant or definitive radiotherapy (RT).Between 1980 and 2001, 28 patients with histologically confirmed esthesioneuroblastoma underwent RT, with a median dose of 60 Gy (range 38-73). The median age was 58 years (range 16-85). According to the Kadish classification, 4 patients had Stage A, 8 Stage B, and 16 Stage C tumors. Radical resection was performed in 13 cases, in 9 before RT and in 4 after RT because of stable or progressive disease. The outcome analyses included the median age (58 years), Kadish stage, skull base penetration, intraorbital extension, resection status, and total dose (or=60 vs.60 Gy).After a mean follow-up of 68 months, 54% of patients were free of tumor progression. The 5- and 10-year local progression-free survival rate was 81% and 51%, respectively, and the disease-free survival rate was 70% and 25%, respectively. Four of ten deaths (4/10) were intercurrent, resulting in a cause-specific survival of 77% and 69% at 5 and 10 years, respectively. Radical resection offered significantly better local progression-free survival and disease-free survival (p0.02). Skull base penetration (p0.04), intraorbital extension (p0.04), and Kadish C stage (p0.06) were important for impaired disease-free survival.Despite doses up to 73 Gy, radical RT cannot replace radical resection, which classifies esthesioneuroblastoma as rather radioresistant. Because of its biology and the high rates of late recurrence, we recommend a radical strategy with resection, high-dose RT, and simultaneous chemotherapy. We are aware that some tumors qualify for palliative treatment only.
- Published
- 2002
- Full Text
- View/download PDF